I'm keeping a very close eye on the progress Phylogica are making with their Macrocyclic Technology. Lot to look forward to in 2014.
Phylogica also made significant progress towards developing a suite of complementary technologies to generate macro-cyclic Phylomer peptides. The overall aim is to integrate these macrocyclic technologies with our genetically encoded screening platforms enabling us to screen billions of cyclised peptide candidates that have been engineered for favourable drug-like properties such as stability and improved potency. These features are highly prized in the pharma industry and hence attract significant commercial values. We look forward to providing further updates as these programmes mature.
Tony
PYC Price at posting:
3.0¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)